Sensei Bio Revenue and Competitors
Estimated Revenue & Valuation
- Sensei Bio's estimated annual revenue is currently $3M per year.
- Sensei Bio's estimated revenue per employee is $77,500
- Sensei Bio's total funding is $58.5M.
Employee Data
- Sensei Bio has 39 Employees.
- Sensei Bio grew their employee count by -29% last year.
Sensei Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | General Counsel | Reveal Email/Phone |
2 | VP Technical Operations and Maryland Site Lead | Reveal Email/Phone |
3 | VP, Preclinical Development | Reveal Email/Phone |
4 | VP Translational Medicine | Reveal Email/Phone |
5 | VP, Finance | Reveal Email/Phone |
6 | SVP Technical Operations and Maryland Site Head | Reveal Email/Phone |
7 | Senior Director, Head Investor Relations | Reveal Email/Phone |
8 | Director, Biologics Discovery & Early Development | Reveal Email/Phone |
9 | Director, Sensei Biotherapeutics | Reveal Email/Phone |
10 | Senior Director Clinical Operations | Reveal Email/Phone |
Sensei Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Sensei Bio?
Sensei Biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. Sensei has pioneered a proprietary immuno-oncology technology platform, called SPIRIT, to aid the immune system in the detection and elimination of cancer. The presence of subtle differences in antigen expression between cancer and normal is key to this process. The SPIRIT platform overcomes disabled immune recognition caused by cancer. The immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy ‘self’ tissues from ‘non-self’. Cancer is a unique challenge to the immune system. It arises from ‘self’ making immune recognition challenging, yet it is known to be altered. Immune recognition of the subtle differences between ‘self’ and ‘non-self’ is key to effective cancer immunotherapy. Headquartered in Gaithersburg, MD, Sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at Brown University.
keywords:N/A
$58.5M
Total Funding
39
Number of Employees
$3M
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sensei Bio News
Sensei Biotherapeutics is a biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an...
Fjällskog joined Faron from Sensei Biotherapeutics (SNSE), a Nasdaq listed immuno-oncology company. As Chief Medical Officer at Sensei, she was...
On March 25, 2021, Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE) closed the transaction. The company has amended the terms of transaction. The company has now raised $34.5 million in the transaction. The company has raised $4.5 million in its second tranche.
Sensei Biotherapeutics, Inc. announced that it will receive funding co-led by existing investor Apeiron Investment Group Ltd. and new investor Catalio Capital Management, LP on January 11, 2021. The transaction also included participation from new investor Pura Vida Investments, LLC, existing in ...
BOSTON & ROCKVILLE, Md.--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc., a clinical-stage cancer immunotherapy company, today announced the successful closing of a $30 million Series B financing. The financing was co-led by existing investor Apeiron Investment Group and new investor Catalio Capit ...
Other Companies in Gaithersburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.1M | 40 | 18% | N/A |
#2 | $3.2M | 40 | -5% | N/A |
#3 | $3.3M | 40 | 8% | N/A |
#4 | $10.8M | 41 | 8% | N/A |
#5 | N/A | 42 | 0% | N/A |